Viking's VK2735 Delivers 22% Weight Loss and Durable Maintenance in Phase 2
VKTX sits 31% above its 52-week low of $24.52 on elevated volume (2.2× avg).
Summary
Viking Therapeutics announced positive Phase 2 maintenance study results for VK2735, showing 22% placebo-adjusted weight loss and strong weight maintenance with less frequent dosing.
Key Events · Product Development and Regulatory · VKTX
-
22% Placebo-Adjusted Weight Loss
Weekly VK2735 17.5 mg achieved 22% placebo-adjusted weight loss at Week 33 with no plateau observed, suggesting continued weight loss with longer dosing.
-
Strong Maintenance with Less Frequent Dosing
Up to 97% of weight loss was maintained with every-other-week dosing and up to 90% with monthly dosing, versus 61% for placebo.
-
Favorable Safety Profile
GI-related adverse event rates during maintenance were similar to placebo, with low discontinuation rates.
-
Phase 3 Program Underway
VK2735 is currently in Phase 3 clinical studies for obesity, with these maintenance results supporting flexible dosing options for long-term weight management.
Analysis · VKTX · Life Sciences
Positive top-line results from the VK2735-102 maintenance study show a 22% placebo-adjusted weight loss at Week 33 with weekly 17.5 mg dosing, with no plateau in sight. The data also reveal that up to 97% of weight loss is maintained with every-other-week dosing and up to 90% with monthly dosing, while GI side effects remain similar to placebo. This represents a major de-risking event for the company's lead obesity program, supporting flexible dosing regimens that could improve adherence and differentiate VK2735 from competitors like semaglutide and tirzepatide. As Viking advances VK2735 into Phase 3 trials, these maintenance results could strengthen its commercial positioning in the highly competitive obesity market.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VKTX was trading at $32.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $24.52 to $43.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.